Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Arousal response in child patients in obstructive sleep apnea].

Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology·2006
Same author

First-principles theory of quantum well resonance in double barrier magnetic tunnel junctions.

Physical review letters·2006
Same author

Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.

Breast cancer research and treatment·2006
Same author

[Identification of two novel mutations of human blood coagulation factor V gene in a Chinese family with congenital factor V deficiency].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics·2006
Same author

Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach.

Journal of proteome research·2006
Same author

Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: dual role of replication and transcription activator.

Journal of virology·2006

Related Experiment Video

Updated: Aug 21, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Targeting exon 20 insertion mutations in lung cancer.

Yaning Yang1, Yan Wang

  • 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.

Current Opinion in Oncology
|November 16, 2022
PubMed
Summary

New targeted therapies show promise for non-small cell lung cancer patients with EGFR exon 20 insertions, offering improved survival outcomes. Ongoing research aims to further enhance treatment efficacy and patient benefits.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.6K

Related Experiment Videos

Last Updated: Aug 21, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have advanced non-small cell lung cancer (NSCLC) care.
  • EGFR exon 20 insertions confer resistance to traditional EGFR-TKIs, limiting survival improvements.
  • This review addresses challenges and advancements in treating NSCLC with EGFR exon 20 insertions.

Approach:

  • Summarizing current treatment strategies for EGFR exon 20 insertion mutations.
  • Reviewing emerging targeted therapies and their clinical efficacy.
  • Discussing historical treatment challenges and future directions in NSCLC therapy.

Key Points:

  • Mobocertinib and amivantamab demonstrate potent antitumor activity against EGFR exon 20 insertions.
  • These agents are FDA-approved for post-first-line treatment in advanced NSCLC.
  • Novel agents like DZD9008 and CLN-081 show promise in ongoing clinical trials.

Conclusions:

  • Targeted therapies offer incremental survival benefits for NSCLC patients with EGFR exon 20 insertions.
  • Continued drug development is crucial for achieving higher response rates and sustained remission.
  • Future research focuses on improving both extracranial and intracranial efficacy for better patient outcomes.